Melatonin Use in Patients With Climacterious Symptoms in the Perimenopause

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 20, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

February 20, 2025

Conditions
Perimenopausal Disorder
Interventions
DRUG

Melatonin 3 MG

patients received 3 mg melatonin in capsule or placebo (capsule identical to the treatment, both in color, taste, odor and shape, composed of cellulose and indigestible fiber) (PALMER, 2020). (GOLTZMAN, 2021) for 30 days (Treister-Goltzman; Peleg, 2021) They will be instructed to ingest melatonin once a day, at night, one hour before bed (PALMER, et al. 2020).

Trial Locations (1)

95900-000

RECRUITING

Gabriela Laste, Lajeado

All Listed Sponsors
collaborator

Aline Patrícia Brietzke

UNKNOWN

collaborator

Ana Paula Costella

UNKNOWN

lead

Univates

OTHER